Literature DB >> 23176220

Angiotensin (1-7) and other angiotensin peptides.

Mitsuru Ohishi1, Koichi Yamamoto, Hiromi Rakugi.   

Abstract

In the classical renin angiotensin system (RAS), angiotensin II Ang IIplays many important roles in cardiovascular disease and in kidney, brain, and other organs via the Ang II type 1 receptor (AT1). The RAS consists of many angiotensin peptides, including Ang (1-7), Ang (1-9), Ang (2-8), and Ang IV. Ang (1-7), produced by angiotensin-converting enzyme 2 (ACE2), has received attention because ACE2-deficient mice have heart failure. In addition, the proto-oncogene mas and insulin regulatory aminopeptidase (IRAP) have been identified as receptors for Ang (1-7) and Ang IV, respectively, accelerating investigations into both peptides. Many groups have suggested that the ACE2/Ang (1-7)/mas axis results in beneficial effects in cardiovascular disease, renal damage, and glucose intolerance and plays an independent role in kidney disease and glucose metabolism. On the other hand, Ang IV/IRAP strongly influences memory disturbance and protects against brain ischemia. Finally, the classical RAS-ACE/Ang II/AT1 axis blockade yields beneficial effects in the context of organ damage, and additional modulation of ACE2/Ang (1-7)/mas or angiotensin IV/IRAP with this blockade results in even greater improvement. In the near future, new treatments targeting RAS and using new angiotensin peptide players might be developed for managing lifestyle-related diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23176220     DOI: 10.2174/1381612811319170013

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  9 in total

1.  Hypertension, cardiovascular disease, and nocturia: a systematic review of the pathophysiological mechanisms.

Authors:  Mitsuru Ohishi; Takuro Kubozono; Koji Higuchi; Yuichi Akasaki
Journal:  Hypertens Res       Date:  2021-03-03       Impact factor: 3.872

2.  Mas receptor mediates cardioprotection of angiotensin-(1-7) against Angiotensin II-induced cardiomyocyte autophagy and cardiac remodelling through inhibition of oxidative stress.

Authors:  Li Lin; Xuebo Liu; Jianfeng Xu; Liqing Weng; Jun Ren; Junbo Ge; Yunzeng Zou
Journal:  J Cell Mol Med       Date:  2015-10-30       Impact factor: 5.310

3.  Cardiovascular effects of small peptides of the renin angiotensin system.

Authors:  Patrícia L Moraes; Lucas M Kangussu; Luiz Gonzaga da Silva; Carlos H Castro; Robson A S Santos; Anderson J Ferreira
Journal:  Physiol Rep       Date:  2017-11

4.  Angiotensin-Converting Enzyme 2 in the Rostral Ventrolateral Medulla Regulates Cholinergic Signaling and Cardiovascular and Sympathetic Responses in Hypertensive Rats.

Authors:  Yu Deng; Xing Tan; Miao-Ling Li; Wei-Zhong Wang; Yang-Kai Wang
Journal:  Neurosci Bull       Date:  2018-10-15       Impact factor: 5.203

Review 5.  Neuropathies and neurological dysfunction induced by coronaviruses.

Authors:  Mina Gholami; Sepideh Safari; Luis Ulloa; Majid Motaghinejad
Journal:  J Neurovirol       Date:  2021-05-13       Impact factor: 3.739

6.  COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases.

Authors:  Yuanyuan Zhang; Mingjie Wang; Xian Zhang; Tianxiao Liu; Peter Libby; Guo-Ping Shi
Journal:  Cardiol Discov       Date:  2021-11-22

Review 7.  A Role for the Brain RAS in Alzheimer's and Parkinson's Diseases.

Authors:  John W Wright; Leen H Kawas; Joseph W Harding
Journal:  Front Endocrinol (Lausanne)       Date:  2013-10-25       Impact factor: 5.555

8.  Angiotensin 1-7 modulates molecular and cellular processes central to the pathogenesis of prostate cancer.

Authors:  Kamila Domińska; Piotr Okła; Karolina Kowalska; Dominika Ewa Habrowska-Górczyńska; Kinga Anna Urbanek; Tomasz Ochędalski; Agnieszka Wanda Piastowska-Ciesielska
Journal:  Sci Rep       Date:  2018-10-25       Impact factor: 4.379

9.  Speculation is not evidence: antihypertensive therapy and COVID-19.

Authors:  Giovanni de Simone; Costantino Mancusi
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2020-07-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.